OncoCyte (NYSEAMERICAN:OCX) has been given a $8.00 price target by analysts at Chardan Capital in a research report issued to clients and investors on Friday, TipRanks reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 46.79% from the company’s previous close.
Several other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of OncoCyte from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th. Piper Jaffray Companies assumed coverage on shares of OncoCyte in a research note on Wednesday, February 13th. They issued an “overweight” rating and a $6.00 target price for the company. Janney Montgomery Scott upgraded shares of OncoCyte from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 29th. Finally, Lake Street Capital upped their target price on shares of OncoCyte from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, January 29th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $6.00.
OCX stock traded up $0.37 during midday trading on Friday, reaching $5.45. 609,059 shares of the company’s stock traded hands, compared to its average volume of 932,705. OncoCyte has a 52 week low of $1.16 and a 52 week high of $6.92.
OncoCyte (NYSEAMERICAN:OCX) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of OncoCyte in the 1st quarter worth about $47,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of OncoCyte in the 1st quarter worth about $3,431,000. Morgan Stanley boosted its holdings in shares of OncoCyte by 43.3% in the 1st quarter. Morgan Stanley now owns 42,172 shares of the biotechnology company’s stock worth $167,000 after buying an additional 12,735 shares during the last quarter. ExodusPoint Capital Management LP purchased a new position in shares of OncoCyte in the 1st quarter worth about $41,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of OncoCyte in the 1st quarter worth about $53,000.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Featured Story: Google Finance Portfolio Workaround
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.